Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity

Modified Adenine (9-Benzyl-2-Butoxy-8-Hydroxyadenine) Redirects Th2-Mediated Murine Lung Inflammation by Triggering TLR7

(2014) A. Vultaggio et al.   JOURNAL OF IMMUNOLOGY

Guide to Receptors and Channels (GRAC), 5th edition

(2011) SPH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)

(2011) M D Fidock et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cutting Edge: Type I IFN Reverses Human Th2 Commitment and Stability by Suppressing GATA3

(2010) J. P. Huber et al.   JOURNAL OF IMMUNOLOGY

Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept

(2010) Ayumu Kurimoto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bifurcation of Toll-Like Receptor 9 Signaling by Adaptor Protein 3

(2010) M. Sasai et al.   SCIENCE

Regulation of Adaptive Immunity by the Innate Immune System

(2010) A. Iwasaki et al.   SCIENCE

Comparison of human B cell activation by TLR7 and TLR9 agonists

(2008) John A Hanten et al.   BMC IMMUNOLOGY

Pathogenesis of Asthma

(2008) STEPHEN T. HOLGATE   CLINICAL AND EXPERIMENTAL ALLERGY

Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer

(2008) Lei Wan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Signalling pathways leading to IFN-α production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications

(2008) C. Guiducci et al.   JOURNAL OF INTERNAL MEDICINE